NCT03627728View on ClinicalTrials.gov

Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

June 21, 2022

Study Completion Date

October 31, 2024

Conditions
Gastric Cancer
Interventions
DRUG

Regorafenib

regorafenib/placebo

OTHER

placebo

regorafenib/placebo

Trial Locations (1)

42123

Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova, Reggio Emilia

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Gruppo Oncologico Italiano di Ricerca Clinica

OTHER